HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lemckert, A. A. C. Articles by Havenga, M. J. E. Search for Related Content PubMed PubMed Citation Articles by Lemckert, A. A. C. Articles by Havenga, M. J. E. Agricola Articles by Lemckert, A. A. C. Articles by Havenga, M. J. E.

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity

¹ Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
² Gaubius Laboratory, TNO, 2301 CA Leiden, The Netherlands
³ Department of Human Retrovirology, Academic Medical Center, Amsterdam, The Netherlands
⁴ Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
⁵ Department of Surgery, LUMC, Leiden, The Netherlands

Correspondence
Menzo J. E. Havenga
m.havenga{at}crucell.com

Recombinant adenoviral vectors based on type 5 (rAd5) show great promise as a vaccine carrier. However, neutralizing activity against Ad5 is prevalent and high-titred among human populations, and significantly dampens Ad5-based vaccine modalities. The generation of alternative adenoviral vectors with low seroprevalence thus receives much research attention. Here, it is shown that a member from human adenovirus subgroup D, i.e. Ad49, does not cross-react with Ad5 neutralizing activity, making it a candidate serotype for vector development. Therefore, a plasmid system that allows formation of replication-incompetent adenovirus serotype 49 vaccine vectors (rAd49) was constructed and it was demonstrated that rAd49 can be successfully propagated to high titres on existing Ad5.E1-complementing cell lines such as PER.C6. Using an rAd49 vector carrying the luciferase marker gene, detailed seroprevalence studies were performed, demonstrating that rAd49 has low seroprevalence and neutralizing antibody titres worldwide. Also, we have initiated rAd49 vector receptor usage suggesting that rAd49 utilizes hCD46 as a cellular receptor. Finally, the immunogenicity of the rAd49 vector was assessed and it was shown that an rAd49.SIVGag vaccine induces strong anti-SIVGag CD8⁺ T-lymphocytes in naïve mice, albeit less than an rAd5.SIVGag vaccine. However, in mice with high anti-Ad5 immunity the rAd5.SIVGag vaccine was severely blunted, whereas the anti-SIVGag response was not significantly suppressed using the rAd49.SIVGag vaccine. These data demonstrate the potential of a replication deficient human group D adenoviral vector for vaccination purposes.

The GenBank/EMBL/DDBJ accession number of the sequence reported in this paper is DQ393829.

This article has been cited by other articles:

				L. H. Haut and H. C. J. Ertl Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine J. Leukoc. Biol., October 1, 2009; 86(4): 779 - 793. [Abstract] [Full Text] [PDF]

				J. Liu, B. A. Ewald, D. M. Lynch, M. Denholtz, P. Abbink, A. A. C. Lemckert, A. Carville, K. G. Mansfield, M. J. Havenga, J. Goudsmit, et al. Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys J. Virol., May 15, 2008; 82(10): 4844 - 4852. [Abstract] [Full Text] [PDF]

				C. Fleischli, D. Sirena, G. Lesage, M. J. E. Havenga, R. Cattaneo, U. F. Greber, and S. Hemmi Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor J. Gen. Virol., November 1, 2007; 88(11): 2925 - 2934. [Abstract] [Full Text] [PDF]

				P. Abbink, A. A. C. Lemckert, B. A. Ewald, D. M. Lynch, M. Denholtz, S. Smits, L. Holterman, I. Damen, R. Vogels, A. R. Thorner, et al. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D J. Virol., May 1, 2007; 81(9): 4654 - 4663. [Abstract] [Full Text] [PDF]

				A. R. Thorner, A. A. C. Lemckert, J. Goudsmit, D. M. Lynch, B. A. Ewald, M. Denholtz, M. J. E. Havenga, and D. H. Barouch Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity J. Virol., December 15, 2006; 80(24): 12009 - 12016. [Abstract] [Full Text] [PDF]